Polycystic Kidney Disease Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Poxel Announces PXL770 Granted Orphan Drug Designation from the U.S. FDA for Autosomal-Dominant Polycystic Kidney Disease (ADPKD)
Completion of preclinical studies support potential to advance PXL770 into Phase 2 development for ADPKD Compelling preclinical efficacy data confirm strategic focus for PXL770 in rare metabolic diseases LYON, France--... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 3, 2022 Category: Pharmaceuticals Source Type: clinical trials

A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
Conditions: Autosomal Dominant Polycystic Kidney Disease; ADPKD; Polycystic Kidney, Autosomal Dominant Interventions: Drug: RGLS8429; Drug: Placebo Sponsor: Regulus Therapeutics Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 30, 2022 Category: Research Source Type: clinical trials

Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease
Condition: Polycystic Kidney, Autosomal Dominant Interventions: Drug: Empagliflozin; Drug: Placebo Sponsors: University of Colorado, Denver; University of Maryland Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 22, 2022 Category: Research Source Type: clinical trials